Antibe Therapeutics is now ranked among the top 10 undervalued stocks in the Medical Devices & Instruments industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
Medical Devices & Instruments: Companies that develop, manufacture, and market medical and surgical equipment and machinery, including orthopedic products, respiratory care equipment, x-ray equipment, laser systems, implants, pacemakers, and other major medical machines and apparatus. Stocks in this category are held primarily for capital appreciation.
More about Antibe Therapeutics
All data provided as-at market close December 22, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Antibe Therapeutics Antibe Therapeutics Inc is a healthcare company. It is engaged in the development of patents and out-licensing of improved compounds of existing drugs. The company has two primary business segments: Antibe Therapeutics and Citagenix. Antibe Therapeutics is listed under ATE on the Toronto Stock Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs. StockCalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. StockCalc's Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including: Discounted Cash Flow (DCF), Price & Other Comparables, Multiples, Adjusted Book Value (ABV) and Analyst Consensus
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.